HAPLN1 mediates collagen remodeling during aging to influence melanoma and immune cell motility

Information

  • Research Project
  • 9229646
  • ApplicationId
    9229646
  • Core Project Number
    F99CA212437
  • Full Project Number
    1F99CA212437-01
  • Serial Number
    212437
  • FOA Number
    RFA-CA-16-005
  • Sub Project Id
  • Project Start Date
    9/21/2016 - 7 years ago
  • Project End Date
    8/31/2018 - 5 years ago
  • Program Officer Name
    MCGUIRL, MICHELE
  • Budget Start Date
    9/21/2016 - 7 years ago
  • Budget End Date
    8/31/2017 - 6 years ago
  • Fiscal Year
    2016
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/21/2016 - 7 years ago

HAPLN1 mediates collagen remodeling during aging to influence melanoma and immune cell motility

Project Summary  The  increased  aggressiveness  of  melanoma  in  elderly  patients  leads  to  increased  metastasis  and  therapy resistance in these patients. Our goal in this proposed research is to understand the molecular  mechanisms  underlying  age-­related  increases  in  melanoma  metastasis,  as  well  as  effects  on  the  immune  microenvironment.  Our  overall  hypothesis  is  that  aged  patients  have  changes  in  the  extracellular  matrix  (ECM)  of  the  skin  that  leads  to  differential  motility  of  melanoma  and  the  immune  cells in the tumor.   To test this hypothesis, we will undertake two specific aims that are outlined in the research proposal.  The  proposed  studies  are  based  on  my  findings  from  my  previous  studies  that  aging  affects  the  metastasis  in  melanoma  cells.  My  work  identified  various  proteins  that  are  de-­regulated  during  aging,  and  our  data  showed  a  35-­fold  decrease  in  levels  of  a  collagen  crosslinking  protein,  HAPLN1,  during  aging. Firstly, we will assess the effect of collagen crosslinking mediated by HAPLN1 on mediating the  changes  in  migration  of  melanoma  cells  from  the  tumor.  Secondly,  we  will  focus  on  changes  in  the  infiltration  of  lymphocytes  into  the  tumor  when  age-­related  changes  in  HAPLN1  levels  restructure  the  tumor  ECM.  We  expect  this  research  to  generate  targets  for  therapeutic  implications  in  elderly  melanoma patients.  Apart  from  these  goals,  this  NCI  Predoctoral  to  Postdoctoral  Fellow  Transition  Award  will  allow  me  to  develop  expertise  in  cancer  research  while  providing  me  with  funding  to  support  my  postdoctoral  training.  My  training  plan  outlined  in  this  proposal  will  take  advantage  of  the  extensive  resources  available to me at The Wistar Institute and University of the Sciences in the F99 phase of my training.  During  this  phase,  my  training  will  be  overseen  by  my  mentor,  Dr.  Ashani  Weeraratna  who  has  successfully mentored several postdoctoral and clinical fellows in their academic careers.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    F99
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
    45076
  • Indirect Cost Amount
  • Total Cost
    45076
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    398
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NCI:45076\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF THE SCIENCES PHILADELPHIA
  • Organization Department
    BIOLOGY
  • Organization DUNS
    079497681
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191044495
  • Organization District
    UNITED STATES